Data Integrity : Key Lessons from the 2025 FDA Warning Letters Data Integrity Is a Leadership Problem, Not a Regional One: Lessons from 2025 FDA Warning Letters Executive Summary This report provides an evaluation of US FDA Warning Letters issued in calendar year 2025 that cite 21 CFR 211.68(b), focusing on automated and computerized systems used to generate, process, store, and report CGMP data
The next article examines the regulatory paradox at the center of the peptide landscape, and what it reveals about how modern medicine handles interventions that dont fit its existing categories.
GLP-1 Drugs Reduce Risk of Hospitalization in Heart Failure Patients GLP-1 drugs were associated with a greater than 40% reduction in hospitalization or all-cause mortality
Approval may be on the horizon
The shot is pretty superficial and you usually get through it without much discomfort
Glutaminolysis: a hallmark of cancer metabolism